Common Stock Issuance, Redeemable Common Stock, Common Stock Warrants, and Convertible Preferred Stock - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands |
|
|
|
|
|
|
|
|
|
|
|
1 Months Ended |
3 Months Ended |
6 Months Ended |
12 Months Ended |
22 Months Ended |
|
|
Jul. 15, 2026 |
Nov. 13, 2025 |
Oct. 23, 2025 |
Oct. 10, 2025 |
Aug. 07, 2025 |
Mar. 31, 2025 |
Sep. 11, 2024 |
Aug. 20, 2024 |
Feb. 25, 2024 |
Feb. 17, 2023 |
Sep. 17, 2020 |
Oct. 31, 2025 |
Feb. 29, 2024 |
Jun. 30, 2026 |
Mar. 31, 2026 |
Jun. 30, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
Dec. 31, 2025 |
Dec. 31, 2024 |
Jun. 30, 2026 |
Mar. 13, 2025 |
Mar. 31, 2023 |
| Subsidiary or Equity Method Investee [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Unpaid stock issuance costs |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 0
|
|
|
$ 0
|
|
|
|
$ 0
|
|
|
| Warrants outstanding (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
1,664,475
|
|
|
1,664,475
|
|
1,664,475
|
|
1,664,475
|
|
|
| Common stock, shares outstanding (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
28,813,466
|
|
|
28,813,466
|
|
26,945,426
|
|
28,813,466
|
|
|
| Shares issued upon conversion (in shares) |
|
|
|
5,426,429
|
5,426,429
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock, shares issued (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
28,813,466
|
|
|
28,813,466
|
|
26,945,426
|
|
28,813,466
|
|
|
| Period for warrants to become exercisable after IPO |
|
|
|
|
|
|
|
|
|
|
12 months
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock warrant liabilities |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 753
|
|
|
$ 753
|
|
$ 3,273
|
|
$ 753
|
|
|
| Common stock, par value (in dollars per share) |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 0.0001
|
|
|
$ 0.0001
|
|
$ 0.0001
|
|
$ 0.0001
|
|
|
| Common stock warrant liability adjustment |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 105
|
|
$ 34,753
|
$ (2,520)
|
$ 28,066
|
|
|
|
|
|
| Decrease in common stock warrant liabilities |
|
|
|
$ 46,884
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock converted |
|
|
|
$ 46,884
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 2,439
|
$ 0
|
|
|
|
|
|
| Share Purchased by Exercise (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
|
|
|
|
|
| Shares subject to vesting (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
200,536
|
|
|
200,536
|
|
|
200,536
|
200,536
|
|
|
| Earnout shares vesting period |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5 years
|
|
|
|
| Sandbridge |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary or Equity Method Investee [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of shares subject to forfeiture (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
200,536
|
|
|
|
| Sandbridge | Subsequent Event |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary or Equity Method Investee [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Earnout shares forfeited (in shares) |
200,536
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Class A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary or Equity Method Investee [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shares issued upon conversion (in shares) |
|
|
|
|
|
|
|
2,291,686
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Series A Convertible Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary or Equity Method Investee [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Redemption value |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 11,479
|
|
|
$ 11,479
|
|
|
|
$ 11,479
|
|
|
| Preferred stock, shares issued (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
11,479
|
|
|
11,479
|
|
11,479
|
|
11,479
|
|
|
| Preferred stock, par value (in dollars per share) |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 0.0001
|
|
|
$ 0.0001
|
|
$ 0.0001
|
|
$ 0.0001
|
|
|
| Conversion of stock, shares converted (in shares) |
|
|
|
|
|
|
|
15,721
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Series B Convertible Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary or Equity Method Investee [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Redemption value |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 9,250
|
|
|
$ 9,250
|
|
|
|
$ 9,250
|
|
|
| Preferred stock, shares issued (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
9,250
|
|
|
9,250
|
|
9,250
|
|
9,250
|
|
|
| Preferred stock, par value (in dollars per share) |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 0.0001
|
|
|
$ 0.0001
|
|
$ 0.0001
|
|
$ 0.0001
|
|
|
| Share Purchased by Exercise (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
|
|
|
|
|
| Redeemable Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary or Equity Method Investee [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Sale of stock, shares issued in transaction (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
310,000
|
|
|
|
|
|
|
|
|
| Shares forfeited during the period (in shares) |
|
125,000
|
|
|
|
62,500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
187,500
|
|
|
| Common stock, shares outstanding (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
252,500
|
|
|
252,500
|
|
|
|
252,500
|
|
|
| Preferred stock, shares issued (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
252,500
|
|
|
252,500
|
|
562,500
|
|
252,500
|
|
|
| Titan Warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary or Equity Method Investee [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants outstanding (in shares) |
|
|
|
|
|
|
125,405
|
|
|
|
|
|
|
95,308
|
|
|
95,308
|
|
95,308
|
|
95,308
|
|
|
| Exercise price of warrant (in dollars per share) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 4.63
|
|
| Warrants expiration period |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5 years
|
|
| Warrants exercised (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
30,097
|
|
|
30,097
|
|
|
|
30,097
|
|
|
| Compensation cost, warrants |
|
|
|
|
|
|
$ 382
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share Purchased by Exercise (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
|
|
|
|
|
| Series B Warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary or Equity Method Investee [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants outstanding (in shares) |
|
|
|
|
|
1,799,021
|
|
|
|
|
|
|
|
0
|
|
|
0
|
|
|
|
0
|
|
|
| Number of securities called by warrants (in shares) |
|
|
|
|
1,799,021
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Share Purchased by Exercise (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
|
|
|
|
|
| February 2023 Warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary or Equity Method Investee [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Aggregate estimated fair value of warrants |
|
|
|
|
|
|
|
|
|
$ 26,133
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net proceeds from issuance of preferred stock and warrants |
|
|
|
|
|
|
|
|
|
$ 3,867
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock, shares issued (in shares) |
|
|
|
|
|
|
|
|
|
7,871,712
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Proceeds from issuance of preferred stock |
|
|
|
|
|
|
|
|
|
$ 30,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| February 2023 Warrants | Series A Convertible Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary or Equity Method Investee [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Preferred stock, shares issued (in shares) |
|
|
|
|
|
|
|
|
|
30,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Preferred stock, par value (in dollars per share) |
|
|
|
|
|
|
|
|
|
$ 0.0001
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Series A Warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary or Equity Method Investee [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants outstanding (in shares) |
|
|
|
|
|
7,871,712
|
|
|
|
|
|
|
|
265,597
|
|
|
265,597
|
|
265,597
|
|
265,597
|
|
|
| Number of securities called by warrants (in shares) |
|
|
|
|
7,215,737
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shares issuable (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
265,597
|
|
|
265,597
|
|
|
|
265,597
|
|
|
| Share Purchased by Exercise (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
|
|
|
|
|
| Series A Warrants | Valuation Technique, Black-Scholes-Merton Model |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary or Equity Method Investee [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise price of warrant (in dollars per share) |
|
|
|
|
$ 4.66
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shares issuable (in shares) |
|
|
|
|
4,412,930
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Private Placement Warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary or Equity Method Investee [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Sale of number of warrants (in shares) |
|
|
|
|
|
|
|
|
|
|
471,428
|
|
|
|
|
|
|
|
|
|
|
|
|
| SBG Public Warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary or Equity Method Investee [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants outstanding (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
821,428
|
|
|
821,428
|
|
821,428
|
|
821,428
|
|
|
| Warrants expiration period |
|
|
|
|
|
|
|
|
|
|
|
|
|
5 years
|
|
|
5 years
|
|
|
|
5 years
|
|
|
| Share Purchased by Exercise (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
|
|
|
|
|
| SVB Warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary or Equity Method Investee [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants outstanding (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
10,714
|
|
|
10,714
|
|
10,714
|
|
10,714
|
|
|
| Exercise price of warrant (in dollars per share) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 5.32
|
| Common stock warrant liabilities |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 0
|
|
|
$ 0
|
|
|
|
$ 0
|
|
|
| Number of securities called by warrants (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10,714
|
| Value of warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 43
|
| Share Purchased by Exercise (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
|
|
|
|
|
|
| Series A and B Warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary or Equity Method Investee [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock warrant liability adjustment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 23,278
|
|
|
|
|
| Public Stock Offering |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary or Equity Method Investee [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Sale of stock, shares issued in transaction (in shares) |
|
|
|
|
|
|
3,135,136
|
|
|
|
|
4,825,400
|
|
|
|
|
|
|
|
|
|
|
|
| Sale of stock, price per share (in dollars per share) |
|
|
|
|
|
|
$ 3.70
|
|
|
|
|
$ 7.15
|
|
|
|
|
|
|
|
|
|
|
|
| Consideration received |
|
|
|
|
|
|
$ 10,590
|
|
|
|
|
$ 32,109
|
|
|
|
|
|
|
|
|
|
|
|
| Offering expenses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 639
|
|
|
|
|
| Public Stock Offering - Initial Shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary or Equity Method Investee [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Sale of stock, shares issued in transaction (in shares) |
|
|
4,196,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Over-Allotment Option |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary or Equity Method Investee [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Sale of stock, shares issued in transaction (in shares) |
|
|
629,400
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Private Placement |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary or Equity Method Investee [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Sale of stock, shares issued in transaction (in shares) |
|
|
|
|
|
|
750,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Private Placement | Series B Convertible Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary or Equity Method Investee [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Preferred stock, shares issued (in shares) |
|
|
|
|
|
|
|
|
9,250
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Preferred stock, par value (in dollars per share) |
|
|
|
|
|
|
|
|
$ 0.0001
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock, shares issued (in shares) |
|
|
|
|
|
|
|
|
1,799,021
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Proceeds from issuance of preferred stock |
|
|
|
|
|
|
|
|
$ 9,250
|
|
|
|
$ 9,250
|
|
|
|
|
|
|
|
|
|
|
| Common stock, par value (in dollars per share) |
|
|
|
|
|
|
|
|
$ 0.0001
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Private Placement | Redeemable Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary or Equity Method Investee [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Sale of stock, shares issued in transaction (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
310,000
|
|
|
|
|
|
|
|
|
| Initial Public Offering | Public Shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary or Equity Method Investee [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Units issued (in shares) |
|
|
|
|
|
|
|
|
|
|
821,428
|
|
|
|
|
|
|
|
|
|
|
|
|
| Initial Public Offering | Public Warrant |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary or Equity Method Investee [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise price of warrant (in dollars per share) |
|
|
|
|
|
|
|
|
|
|
$ 161.00
|
|
|
|
|
|
|
|
|
|
|
|
|
| Twelve Point Five Zero Stock Price |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary or Equity Method Investee [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shares subject to vesting (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
100,268
|
|
|
|
| Share price (in dollars per share) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 175.00
|
|
|
|
| Fifteen Point Zero Zero Stock Price |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Subsidiary or Equity Method Investee [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Shares subject to vesting (in shares) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
100,268
|
|
|
|
| Share price (in dollars per share) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 210.00
|
|
|
|